Raloxifene hydrochloride, solid

Not available outside of the UK & Ireland.

Application

Raloxifene hydrochloride has been used: as a competitive inhibitors for estrogen receptor α in breast cancer cells as an anti-resorptive agents to test its effect on improving bone mineral density (BMD) in six-month-old female ovariectomized ratsto test effect on viability of esophageal adenocarcinoma cells

Biochem/physiol Actions

Raloxifene is a selective estrogen receptor modulator (SERM); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.

Raloxifene is benzothiophene compound and is used in treating postmenopausal osteoporosis It comparatively induces lesser risk in developing thromboembolic events and cataracts compared to tamoxifen. Raloxifene also interacts with estrogen receptors and plasma proteins.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

1 g in poly bottle

500 mg in poly bottle